Back
Non-Moderated Poster Abstract
Eposter Presentation
 
Accept format: PDF. The file size should not be more than 5MB
 
Accept format: PNG/JPG/WEBP. The file size should not be more than 2MB
 
Submitted
Abstract
Balancing Survival and Quality of Life: Optimizing Treatment for Locally and Regionally Advanced Prostate Cancer
Moderated Poster Abstract
Clinical Research
Oncology: Prostate
Author's Information
8
No more than 10 authors can be listed (as per the Good Publication Practice (GPP) Guidelines).
Please ensure the authors are listed in the right order.
Taiwan
Ho Li liho0827@gmail.com Tri-Service General Hospital, National Defense Medical Center Division of Urology, Department of Surgery Taipei Taiwan * Gangshan Branch of Zuoying Armed Forces General Hospital Division of Urology, Department of Surgery Kaohsiung Taiwan
Chih-Wei Tsao weisurger@gmail.com Tri-Service General Hospital, National Defense Medical Center Division of Urology, Department of Surgery Taipei Taiwan -
En Meng qop811027@gmail.com Tri-Service General Hospital, National Defense Medical Center Division of Urology, Department of Surgery Taipei Taiwan -
Guang-Huan Sun joshuatree.amber@gmail.com Tri-Service General Hospital, National Defense Medical Center Division of Urology, Department of Surgery Taipei Taiwan -
Dah-Shyong Yu michael40315@yahoo.com.tw Tri-Service General Hospital, National Defense Medical Center Division of Urology, Department of Surgery Taipei Taiwan -
Sheng‐Tang Wu wushentang89@gmail.com Tri-Service General Hospital, National Defense Medical Center Division of Urology, Department of Surgery Taipei Taiwan -
Tai-Lung Cha paosheng980279@gmai.com Tri-Service General Hospital, National Defense Medical Center Division of Urology, Department of Surgery Taipei Taiwan -
Ming-Hsin Yang yangming@ndmctsgh.edu.tw Tri-Service General Hospital, National Defense Medical Center Division of Urology, Department of Surgery Taipei Taiwan -
 
 
 
 
 
 
 
 
 
 
 
 
Abstract Content
Men diagnosed with locally advanced prostate cancer (LAPCa) or regionally advanced prostate cancer (RAPCa) face significant mortality risks. Current clinical guidelines advocate for multimodal treatment strategies, including radical prostatectomy (RP) followed by radiotherapy (RT) and RT combined with androgen deprivation therapy (ADT). However, comparative data on these treatment modalities remain limited, particularly in Asian populations. Moreover, the increasing use of robotic-assisted radical prostatectomy (RARP) may impact surgical precision, complication rates, and functional outcomes, potentially altering treatment-related morbidity and survival. This study aims to evaluate the survival outcomes, adverse effects, and quality of life (QoL) in patients receiving RP plus RT versus RT plus ADT in a single-institution cohort.
This retrospective cohort study included 252 patients diagnosed with cT3-T4N0M0 (LAPCa) or cT3-T4N1M0 (RAPCa) prostate cancer between 2014-2024. Propensity score matching was applied to balance baseline characteristics between the two treatment groups. Survival outcomes were analyzed using the Kaplan-Meier method, and multivariable Cox proportional hazards models were employed to assess the impact of treatment modality on cancer-specific and overall survival. Adverse effects, including erectile dysfunction and urinary incontinence, were documented through follow-up records. QoL outcomes were evaluated using validated patient-reported measures.
From 2014 to 2024, 252 men (≥60 years old) were diagnosed with LAPCa or RAPCa: 59% received RP plus RT, and 41% received RT plus ADT. Regardless of the tumor stage or the Gleason score, the adjusted 5-year prostate cancer–specific survival and 5-year overall survival favored men who underwent RP plus RT over men who underwent RT plus ADT. However, RARP plus XRT versus XRT plus ADT was associated with poorer quality of life.
Men with LAPCa or RAPCa treated initially with RP plus RT had a lower risk of prostate cancer–specific death and improved overall survival in comparison with those men treated. However, with RARP, pateints experienced poorer quality of life.
Prostate Cancer, Locally Advanced Prostate Cancer (LAPCa), Regionally Advanced Prostate Cancer (RAPCa), Radical Prostatectomy (RP), Radiotherapy (RT), Androgen Deprivation Therapy (ADT), Robotic-Assisted Radical Prostatectomy (RARP), Quality of Life (QoL), Survival Outcomes, Propensity Score Matching, Asian Population
 
 
 
 
 
 
 
 
 
 
1918
 
Presentation Details